

Regis vs PetMed Express
Regis Corporation operates salon brands across thousands of locations navigating a franchise transition, while PetMed Express sells pet medications online competing against vet clinics and Amazon. Both companies face structural disruption in their core markets and have struggled to sustain revenue growth. Regis vs PetMed Express compares two turnaround situations where customer retention and digital strategy will determine whether either can rebuild durable earnings power.
Regis Corporation operates salon brands across thousands of locations navigating a franchise transition, while PetMed Express sells pet medications online competing against vet clinics and Amazon. Bot...
Investment Analysis

Regis
RGS
Pros
- Regis Corp. showed revenue growth to $210.13 million in fiscal 2025, increasing 3.52% year-over-year, indicating a positive sales momentum.
- The company has a low price-to-earnings ratio of 0.61, suggesting potential undervaluation relative to earnings.
- Analysts project strong long-term price appreciation for Regis stock, with forecasts exceeding 500% growth by 2040-2050.
Considerations
- Recent technical signals indicate a negative short- and long-term outlook with ongoing sell signals and potential for further price declines.
- Regis exhibits higher than average stock price volatility with a beta of 1.47, exposing investors to increased market risk.
- Revenue has shown some volatility with a 4.88% decline in the last twelve months and inconsistent quarterly growth trends.

PetMed Express
PETS
Pros
- PetMed Express offers a high dividend yield near 14%, providing strong income potential for investors.
- The company operates in the niche pet pharmaceutical market, catering to growing direct-to-consumer demand for pet medications and health products.
- Recent leadership additions to the board signal potential governance improvements and strategic direction clarity.
Considerations
- PetMed Express has a high price-to-earnings ratio around 57, indicating expensive valuation relative to earnings.
- The stock price has experienced a wide 52-week range, suggesting considerable recent price instability and market uncertainty.
- The company’s smaller market cap and employee base highlight potential limitations in scale and operational leverage compared to larger competitors.
Buy RGS or PETS in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.


